Domainex Ltd, a privately-owned drug discovery services company, has been awarded £118,000 from the UK’s innovation agency, Innovate UK, to develop a new biophysical screening method for G-protein coupled receptors (GPCRs). This investment represents a significant opportunity for the company to develop a technology to accelerate the discovery of new drugs.
On Thursday we released our joint report with the Medicines Discovery Catapult ‘State of the Discovery Nation 2018’. Launched by Sir Mark Walport at Alderley Park, the report is based on surveys and over 100 in-depth interviews with senior executives of UK drug discovery companies and shows that global R&D productivity is under unprecedented pressure. The BIA, along with the Medicines Discovery Catapult, is committed to working with others to create long-term solutions to these issues, which will drive productivity and further success in the important years ahead.
Freeline will develop a ‘next-generation’ therapy platform at CGT Catapult’s UK-based large-scale GMP manufacturing centre. The company will further develop proprietary viral vector manufacturing technology for bleeding and other disorders.
On Friday 12 January 2018, the Alliance held a launch event for their first, highly anticipated progress report at Chatham House in London. BIA CEO and Vice-Chair of the International Confederation of Biotech Associations (ICBA), Steve Bates, was invited to speak as part of an expert and media roundtable briefing, alongside other global leaders in this fight.
In this blog, we take a brief look at what they discussed, and some of the key take-home messages from the report.
Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwickshire which have achieved success for themselves, their staff and their customers.
Repligen Corporation (NASDAQ:RGEN) announces its extended long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands at Repligen's facilities in Waltham, MA and Lund, Sweden.